Comparison of Abbott AxSYM and Roche Elecsys 2010 for measurement of BNP and NT-proBNP

Chien, Tzu-I; Chen, Hui-hou; Kao, Jau-Tsuen

doi:10.1016/j.cca.2006.01.017

Cited by 33 publications

(18 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Measurements were performed on an Elecsys 2010 instrument (Roche Diagnostics, Basel, Switzerland) using a sandwich immunoassay. The reported coefficient of variation for this assay is 0.9-2.2% [25].…”

Section: Methodsmentioning

confidence: 85%

Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension

Mathai¹,

Bueso²,

Hummers³

et al. 2009

European Respiratory Journal

117

View full text Add to dashboard Cite

N-terminal pro-brain natriuretic peptide (NT-proBNP) is a marker of neurohormonal activation that is useful in the diagnosis and prognosis of various forms of pulmonary arterial hypertension (PAH). We sought to characterise and compare NT-proBNP in a cohort of PAH related to systemic sclerosis (PAH-SSc) and idiopathic PAH (IPAH) patients.NT-proBNP levels, collected from PAH-SSc and IPAH patients followed prospectively, were compared and correlated with haemodynamic variables. Cox proportional hazard models were created to assess the predictive value of NT-proBNP.98 patients (55 PAH-SSc, 43 IPAH) were included. Haemodynamics were similar, except for lower mean pulmonary arterial pressure in PAH-SSc. NT-proBNP levels were significantly higher in PAH-SSc (3,419¡3,784 versus 1,393¡1,633 pg?mL -1 ; p,0.01) and were more closely related to haemodynamics in PAH-SSc than IPAH. 28 patients died. NT-proBNP predicted survival (hazard ratio (HR) 3.18; p,0.01) in the overall cohort; however, when stratified by group, predicted survival only in PAH-SSc (HR 3.07, p,0.01 versus 2.02, p50.29 in IPAH). This is the first description showing NT-proBNP levels are 1) significantly higher in PAH-SSc than IPAH despite less severe haemodynamic perturbations, and 2) stronger predictors of survival in PAH-SSc, suggesting that neurohormonal regulation may differ between PAH-SSc and IPAH. Future studies to define pertinent mechanisms are warranted.

show abstract

Section: Methodsmentioning

confidence: 85%

Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension

Mathai¹,

Bueso²,

Hummers³

et al. 2009

European Respiratory Journal

117

View full text Add to dashboard Cite

show abstract

“…Although serum, heparin plasma or whole blood are all specimens of choice for NT-proBNP, EDTA plasma yields a consistent negative bias compared to matched serum samples (18). Additionally, the longer in vitro stability of NTproBNP (up to 7 days) compared to BNP (a few hours) is favorable when there may be delays in sample delivery (19)(20)(21)(22). Although several studies reported an age and gender dependency of BNP and NT-proBNP concentrations in healthy as well as in chronic HF patients (20,(23)(24)(25)(26)(27), most laboratories used the decision limits recommended by the manufacturers based only on one cut-off concentration for HF.…”

Section: Discussionmentioning

confidence: 99%

A pilot survey of the use and implementation of cardiac markers in acute coronary syndrome and heart failure across Europe The CARdiac MArker Guideline Uptake in Europe (CARMAGUE) study

Pulkki¹,

Suvisaari²,

Collinson³

et al. 2009

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Background: Guidelines on preferred cardiac marker strategies for investigation of patients with acute coronary syndromes (ACS) are available from the laboratory medicine and cardiology communities. Therefore, implementation of these guidelines into daily clinical practice should be a joint effort of laboratory specialists and clinicians. This was investigated in this survey. Methods: A pilot study was performed sponsored by the European Federation of Clinical Chemistry and Laboratory Medicine. A link to an online questionnaire was e-mailed to 990 laboratories from eight European countries in May 2006. The requested information included tests performed, clinical protocol development, and reference limits. Results: We obtained a total of 220 responses. Out of these, 208 responses (95%) were from hospitals that provide 24-h admission of patients. The suggested turn-around-time (-60 min) was apparently met by

show abstract

“…In a different study, with regards to analytical performance, the NTproBNP Dade Behring assay demonstrated a higher accuracy and is highly recommended for the follow-up of HF treatment, although the BNP Biosite assay was faster because analysis is performed on whole blood [37]. The precision and stability for NTproBNP was better than for BNP according to Chien et al [101].…”

Section: Heart Failurementioning

confidence: 98%

BNP or NTproBNP? A clinician's perspective

Steiner

Guglin

2008

International Journal of Cardiology

View full text Add to dashboard Cite

Comparison of Abbott AxSYM and Roche Elecsys 2010 for measurement of BNP and NT-proBNP

Cited by 33 publications

References 19 publications

Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension

Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension

A pilot survey of the use and implementation of cardiac markers in acute coronary syndrome and heart failure across Europe The CARdiac MArker Guideline Uptake in Europe (CARMAGUE) study

BNP or NTproBNP? A clinician's perspective

Contact Info

Product

Resources

About